Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Xocova, Astellas’s Gastric Cancer Med Up for PAFSC Review on March 4; Pfizer’s Bispecific, RSV Jab Also on Agenda
February 20, 2024
- MHLW Announces Revised Rule for Info Disclosure of Physician Payments
February 19, 2024
- 12 VEGF Inhibitors Ordered to Add Artery Dissection Risk to ADR List
February 19, 2024
- Chugai’s PNH Med, Takeda’s cTTP Therapy Up for Advisory Panel Review on Feb. 29
February 16, 2024
- Japan Approves 1st Generics for 4 APIs towards June Listing, All See AGs
February 16, 2024
- Japan to Ponder New COVID Vaccine Composition from Spring
February 15, 2024
- Japan to Announce New Drug Prices on March 5
February 15, 2024
- AMED Chief Eyes 20-30% Team Expansion by FY2029
February 14, 2024
- Sawai and Kaigen Submit Biz Improvement Plans to Osaka Govt
February 14, 2024
- MHLW to Review Pig Kidney Transplant Plan Including Ethical Issues: Minister
February 14, 2024
- Chuikyo Issues 2024 Reform Recommendation; 1,000 Yen Premium Set for Inpatient Biosimilar Use
February 14, 2024
- Active Pharma Slapped with Biz Improvement Order for Illicit API Production
February 13, 2024
- MHLW Panel to Draw Up Report by Year-End towards Amendment of PMD Act
February 13, 2024
- Maintain Funding for COVID Pill beyond April: Academic Societies to Govt
February 13, 2024
- Japan Approves Jardiance for CKD, Label Expansion for Opdivo and More
February 13, 2024
- Japan to Allow Submissions without Japanese Data If All Requirements Met
February 9, 2024
- FPMAJ Supports Generic Industry Consortia Concept but Frets Antitrust Issues
February 9, 2024
- Health Minister Admits Antitrust Challenge in Generic Industry Revamp
February 9, 2024
- Takeda’s Acquired Hemophilia A Drug Up for Panel Review on February 22
February 9, 2024
- New Govt Forum Moots US-Level Trial Environment, Priority Review Vouchers
February 9, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…